Pembrolizumab active as first-line therapy in renal cell carcinoma subtype

Pembrolizumab monotherapy in the first-line setting induced a response among nearly 40% of patients with clear cell renal cell carcinoma across all IMDC risk groups, according to interim results from cohort A of the KEYNOTE-427 trial presented at the ASCO Annual Meeting.

Pembrolizumab active as first-line therapy in renal cell carcinoma subtype2018-07-27T16:42:06-04:00